Jump to:Page Content
The plaintiff, an obstetrician and gynecologist, alleged Botox’s manufacturer failed to warn of the drug’s risks. Suit also alleged that the defendant improperly promoted Botox for off-label use at higher-than-approved doses through a vigorous campaign that included delivering off-label dosing schedules to health care providers. The jury awarded $15 million. Helton v. Allergan, Inc.
The Products Liability Law Reporter is endowed by Perry & Haas, L.L.P., and Robb & Robb, LLC
The endowers have no control over the placement of information or the editorial content of the Products Liability Law Reporter.